{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:27:17Z","timestamp":1793600837935,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ygyno.2026.02.019","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:53:52Z","timestamp":1773269632000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Peritoneal cancer risk after risk reducing salpingo-oophorectomy, impact of mutational status and STIC lesions"],"prefix":"10.1016","volume":"208","author":[{"given":"Claire","family":"Saule","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enora","family":"Laas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bataillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Becette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Perlbarg-Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Donnadieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aull\u00e8ne","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrystelle","family":"Colas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vincent-Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pasmant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Stoppa-Lyonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Fourchotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Mouret-Fourme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ygyno.2026.02.019_bb0005","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ygyno.2026.02.019_bb0010","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/cncr.22603","article-title":"Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation","volume":"109","author":"Laki","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.019_bb0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00000478-200202000-00003","article-title":"Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or \u22122 mutations: implications for gross examination, cytology, and clinical follow-up","volume":"26","author":"Agoff","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.019_bb0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","article-title":"Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy","volume":"23","author":"Powell","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.019_bb0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","article-title":"Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers","volume":"100","author":"Finch","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.019_bb0030","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal Fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.02.019_bb0035","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/modpathol.2013.212","article-title":"M\u00fcllerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-end protocol","volume":"27","author":"Mingels","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2026.02.019_bb0040","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020","author":"Mb","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2026.02.019_bb0045","unstructured":"Synth\u00e8se - Femmes porteuses d'une mutation de BRCA1 ou BRCA2 \/ D\u00e9tection pr\u00e9coce du cancer du sein et des annexes et strat\u00e9gies de r\u00e9duction du risque - Ref\u00a0: RECOBRCASYNTH17 Institut National Du Cancer [Internet]. [cited 2017 Aug 15]. Available from: http:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Synthese-Femmes-porteuses-d-une-mutation-de-BRCA1-ou-BRCA2-Detection-precoce-du-cancer-du-sein-et-des-annexes-et-strategies-de-reduction-du-risque"},{"issue":"9","key":"10.1016\/j.ygyno.2026.02.019_bb0050","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.019_bb0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/jmedgenet-2013-102015","article-title":"Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants","volume":"51","author":"Jervis","year":"2014","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.019_bb0065","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PGP.0b013e31823b8831","article-title":"Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma","volume":"31","author":"Vang","year":"2012","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.019_bb0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/path.2739","article-title":"Secretory cell outgrowth, PAX2 and serous carcinogenesis in the fallopian tube: secretory cell outgrowth in the fallopian tube","volume":"222","author":"Chen","year":"2010","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.02.019_bb0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/PAP.0b013e3181ecdee1","article-title":"A pathologist\u2019s road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube","volume":"17","author":"Mehrad","year":"2010","journal-title":"Adv. Anat. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.019_bb0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PAS.0000000000000353","article-title":"Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas","volume":"39","author":"Gilks","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.02.019_bb0085","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAS.0000000000000352","article-title":"Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series","volume":"39","author":"Morrison","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.02.019_bb0090","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/1471-0528.14543","article-title":"Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review","volume":"124","author":"Chen","year":"2017","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.019_bb0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/PGP.0b013e31822ea955","article-title":"Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases","volume":"31","author":"Tang","year":"2012","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.02.019_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky061","article-title":"Population frequency of serous tubal intraepithelial carcinoma (STIC) in clinical practice using SEE-Fim protocol","volume":"2","author":"Samimi","year":"2018","journal-title":"JNCI Cancer Spectr."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.019_bb0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2017.04.015","article-title":"Frequency of \u2018incidental\u2019 serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: a six-year study","volume":"146","author":"Meserve","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.019_bb0110","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat. Commun."},{"issue":"25","key":"10.1016\/j.ygyno.2026.02.019_bb0115","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2008.16.4814","article-title":"Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention","volume":"26","author":"Carlson","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.019_bb0120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2019.03.003","article-title":"Retrospective study of a 16\u00a0year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: prevalence of invasive and in-situ carcinoma, with follow-up","volume":"153","author":"Blok","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.019_bb0125","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ygyno.2013.12.009","article-title":"Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations","volume":"132","author":"Conner","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.02.019_bb0130","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2013.01.029","article-title":"Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy","volume":"129","author":"Powell","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.02.019_bb0135","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1940-6207.CAPR-18-0009","article-title":"Fallopian tube lesions in women at high risk for ovarian cancer: a multicenter study","volume":"11","author":"Visvanathan","year":"2018","journal-title":"Cancer Prev. Res. (Phila.)"},{"issue":"17","key":"10.1016\/j.ygyno.2026.02.019_bb0140","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.21.02016","article-title":"Risk of peritoneal carcinomatosis after risk-reducing Salpingo-oophorectomy: a systematic review and individual patient data meta-analysis","volume":"40","author":"Steenbeek","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.02.019_bb0145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ygyno.2024.05.024","article-title":"Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1\/2 germline pathogenic variant carriers","volume":"187","author":"Stroot","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.019_bb0150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.02.019_bb0155","first-page":"219","article-title":"Identification et prise en charge des pr\u00e9dispositions h\u00e9r\u00e9ditaires aux cancers du sein et de l\u2018ovaire (mise \u00e0 jour 2004)","volume":"91","author":"Eisinger","year":"2004","journal-title":"Bull. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.02.019_bb0160","first-page":"51","article-title":"INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and\/or ovarian cancer","volume":"42","author":"Eisinger","year":"1999","journal-title":"Ann. Genet."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826008127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826008127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:35:21Z","timestamp":1793597721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826008127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"alternative-id":["S0090825826008127"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.02.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peritoneal cancer risk after risk reducing salpingo-oophorectomy, impact of mutational status and STIC lesions","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}